Abstract: Methods of directing stem cell fate for therapeutic purposes through the deliberate manipulation of caspase-3 activity are provided. The use of modulators of caspase-3 activity to modulate stem cell differentiation is described including activators and/or effectors of caspase-3, which can be used to induce stem cell differentiation, and inhibitors of caspase-3, which can be used to inhibit differentiation and thereby promote or maintain proliferation of stem cells. Methods of screening for modulators of caspase-3 and the use of such compounds to modulate stem cell differentiation in vitro or in vivo are also provided as are therapeutic applications of the compounds.
Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce an immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences, is herein described.
Type:
Grant
Filed:
August 7, 2000
Date of Patent:
July 19, 2005
Assignees:
Novartis AG, Ottawa Health Research Institute
Inventors:
Steven Griffiths, Rachel Jane Ritchie, Joel Heppell
Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
Type:
Application
Filed:
April 23, 2004
Publication date:
February 24, 2005
Applicants:
Coley Pharmaceutical GmbH, University of Iowa Research Foundation, CPG Immunopharmaceuticals GMBH, Ottawa Health Research Institute
Inventors:
Heather Davis, Joachim Schorr, Arthur Krieg
Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
Type:
Application
Filed:
May 9, 2003
Publication date:
December 4, 2003
Applicants:
Coley Pharmaceutical GmbH, University of Iowa Research Foundation, CPG Immunopharmaceuticals GMBH, Ottawa Health Research Institute
Inventors:
Heather L. Davis, Joachim Schorr, Arthur M. Krieg
Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
Type:
Grant
Filed:
June 3, 1999
Date of Patent:
June 18, 2002
Assignees:
University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
Inventors:
Heather L. Davis, Joachim Schorr, Arthur M. Krieg